Intrapulmonary concentrations of meropenem administered by continuous infusion in critically ill patients with nosocomial pneumonia: a randomized pharmacokinetic trial

Mostra el registre complet Registre parcial de l'ítem

• dc.contributor.author Benítez-Cano, Adela
• dc.contributor.author Luque Pardos, Sònia
• dc.contributor.author Sorli Redó, M. Luisa
• dc.contributor.author Carazo Cordobés, Jesús
• dc.contributor.author Ramos Delgado, M.
• dc.contributor.author Campillo Ambrós, Núria
• dc.contributor.author Curull Serrano, Víctor
• dc.contributor.author Sánchez-Font, Albert
• dc.contributor.author Vilaplana, Carles
• dc.contributor.author Horcajada Gallego, Juan Pablo
• dc.contributor.author Adalia Bartolomé, Ramón
• dc.contributor.author Bermejo Martínez, Silvia
• dc.contributor.author Samsó Sabé, Enric
• dc.contributor.author Hope, William
• dc.contributor.author Grau Cerrato, Santiago
• dc.date.accessioned 2020-05-28T07:33:44Z
• dc.date.available 2020-05-28T07:33:44Z
• dc.date.issued 2020
• dc.description.abstract Background: Optimal antimicrobial drug exposure in the lung is required for successful treatment outcomes for nosocomial pneumonia. Little is known about the intrapulmonary pharmacokinetics (PK) of meropenem when administered by continuous infusion (CI). The aim of this study was to evaluate the PK of two dosages of meropenem (3 g vs 6 g/day by CI) in the plasma and epithelial lining fluid (ELF) in critically ill patients with nosocomial pneumonia. Methods: Thirty-one patients (81% male, median (IQR) age 72 (22) years) were enrolled in a prospective, randomized, clinical trial. Sixteen patients received 1 g/8 h and 15 2 g/8 h by CI (8 h infusion). Plasma and ELF meropenem concentrations were modeled using a population methodology, and Monte Carlo simulations were performed to estimate the probability of attaining (PTA) a free ELF concentration of 50% of time above MIC (50% fT>MIC), which results in logarithmic killing and the suppression of resistance in experimental models of pneumonia. Results: The median (IQR) of meropenem AUC0-24 h in the plasma and ELF was 287.6 (190.2) and 84.1 (78.8) mg h/L in the 1 g/8 h group vs 448.1 (231.8) and 163.0 (201.8) mg h/L in the 2 g/8 h group, respectively. The penetration ratio was approximately 30% and was comparable between the dosage groups. In the Monte Carlo simulations, only the highest approved dose of meropenem of 2 g/8 h by CI allowed to achieve an optimal PTA for all isolates with a MIC < 4 mg/L. Conclusions: An increase in the dose of meropenem administered by CI achieved a higher exposure in the plasma and ELF. The use of the highest licensed dose of 6 g/day may be necessary to achieve an optimal coverage in ELF for all susceptible isolates (MIC ≤ 2 mg/L) in patients with conserved renal function. An alternative therapy should be considered when the presence of microorganisms with a MIC greater than 2 mg/L is suspected.
• dc.format.mimetype application/pdf
• dc.identifier.citation Benítez-Cano A, Luque S, Sorlí L, Carazo J, Ramos I, Campillo N, et al. Intrapulmonary concentrations of meropenem administered by continuous infusion in critically ill patients with nosocomial pneumonia: a randomized pharmacokinetic trial. Crit Care. 2020 Feb 17; 24(1):55. DOI: 10.1186/s13054-020-2763-4
• dc.identifier.doi http://dx.doi.org/10.1186/s13054-020-2763-4
• dc.identifier.issn 1364-8535
• dc.identifier.uri http://hdl.handle.net/10230/44838
• dc.language.iso eng
• dc.publisher BioMed Central
• dc.relation.ispartof Critical Care. 2020 Feb 17;24(1):55
• dc.rights Copyright © The Author(s). 2020. Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
• dc.rights.accessRights info:eu-repo/semantics/openAccess
• dc.rights.uri http://creativecommons.org/licenses/by/4.0/
• dc.subject.keyword Critically ill patients
• dc.subject.keyword Dose selection
• dc.subject.keyword Lung penetration
• dc.subject.keyword Meropenem
• dc.subject.keyword Nosocomial pneumonia
• dc.subject.keyword Pharmacodynamics
• dc.subject.keyword Population pharmacokinetics
• dc.title Intrapulmonary concentrations of meropenem administered by continuous infusion in critically ill patients with nosocomial pneumonia: a randomized pharmacokinetic trial
• dc.type info:eu-repo/semantics/article
• dc.type.version info:eu-repo/semantics/publishedVersion